Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Century Therapeutics (IPSC) Operating Expenses (2022 - 2025)

Century Therapeutics (IPSC) has disclosed Operating Expenses for 4 consecutive years, with $20.7 million as the latest value for Q4 2025.

  • Quarterly Operating Expenses fell 50.19% to $20.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $126.4 million through Dec 2025, down 12.64% year-over-year, with the annual reading at $126.4 million for FY2025, 12.64% down from the prior year.
  • Operating Expenses for Q4 2025 was $20.7 million at Century Therapeutics, down from $36.1 million in the prior quarter.
  • The five-year high for Operating Expenses was $44.0 million in Q4 2023, with the low at $20.7 million in Q4 2025.
  • Average Operating Expenses over 4 years is $34.9 million, with a median of $35.1 million recorded in 2023.
  • The sharpest move saw Operating Expenses skyrocketed 30.16% in 2023, then plummeted 50.19% in 2025.
  • Over 4 years, Operating Expenses stood at $33.8 million in 2022, then surged by 30.16% to $44.0 million in 2023, then decreased by 5.84% to $41.5 million in 2024, then tumbled by 50.19% to $20.7 million in 2025.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $20.7 million, $36.1 million, and $34.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.